Teriflunomide

Multiple Sclerosis
Treatment
1 FDA approval
20 Active Studies for Teriflunomide

What is Teriflunomide

TeriflunomideThe Generic name of this drug
Treatment SummaryTeriflunomide, also known as Aubagio®, is a medication used to treat multiple sclerosis. It works by reducing the activity of the immune system, which helps reduce inflammation and relapses. However, teriflunomide can have serious side effects, such as liver damage and birth defects, so patients must be carefully monitored while taking this medication.
Aubagiois the brand name
image of different drug pills on a surface
Teriflunomide Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Aubagio
Teriflunomide
2013
44

Approved as Treatment by the FDA

Teriflunomide, also known as Aubagio, is approved by the FDA for 1 uses which include Multiple Sclerosis .
Multiple Sclerosis
Helps manage Multiple Sclerosis

Effectiveness

How Teriflunomide Affects PatientsTeriflunomide is a drug that helps to reduce inflammation and prevent cell growth in the central nervous system. It does this by reducing the amount of active white blood cells in the CNS.
How Teriflunomide works in the bodyTeriflunomide works by preventing cells from producing pyrimidine, a compound essential for proper functioning. This stops cells from producing energy and boosts the immune system's ability to fight off MS.

When to interrupt dosage

The suggested measure of Teriflunomide is contingent upon the diagnosed condition. The amount of dosage is contingent upon the delivery approach (e.g. Tablet, film coated or Tablet - Oral) featured in the table beneath.
Condition
Dosage
Administration
Multiple Sclerosis
, 14.0 mg, 7.0 mg
, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet

Warnings

Teriflunomide Contraindications
Condition
Risk Level
Notes
Severe Hepatic Impairment
Do Not Combine
females of reproductive potential
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Teriflunomide.
Common Teriflunomide Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Teriflunomide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Acteoside
Major
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Acteoside.
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Teriflunomide.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Antilymphocyte immunoglobulin (horse).
Bacillus calmette-guerin substrain russian BCG-I live antigen
Major
The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Teriflunomide.
Teriflunomide Toxicity & Overdose RiskWomen who are pregnant or of childbearing age should not take teriflunomide due to the potential risk of birth defects. Additionally, those with severe liver damage should avoid this drug because it can cause liver toxicity, liver failure, and death.
image of a doctor in a lab doing drug, clinical research

Teriflunomide Novel Uses: Which Conditions Have a Clinical Trial Featuring Teriflunomide?

193 active clinical trials are underway to investigate the potential of Teriflunomide to mitigate Multiple Sclerosis symptoms.
Condition
Clinical Trials
Trial Phases
Multiple Sclerosis
127 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1

Teriflunomide Reviews: What are patients saying about Teriflunomide?

3.7Patient Review
8/19/2014
Teriflunomide for Multiple Sclerosis Symptoms Return then Become Less Severe
The medicine appears to be effective, but the side-effects are becoming increasingly unpleasant. In particular, I have experienced worsening diarrhea over the seven months that I've been taking it. Additionally, I have suffered from hair loss and weight loss (though the latter is not necessarily a bad thing). Some of my symptoms have improved since starting this medication regimen.
3.7Patient Review
3/2/2014
Teriflunomide for Multiple Sclerosis Symptoms Return then Become Less Severe
The longer I took this medication, the more side effects developed. These included hair loss, dizziness, feeling lightheaded, visual changes, terrible taste and joint stiffness.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about teriflunomide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is teriflunomide FDA approved?

"The U.S. Food and Drug Administration has approved teriflunomide, a once-daily pill, to treat relapsing forms of MS. This is the second oral disease-modifying therapy approved for the treatment of multiple sclerosis."

Answered by AI

What does Aubagio do to your body?

"Tell your doctor right away if you have any new or worsening skin problems, such as a rash, blisters, peeling skin, redness, or itching.

Aubagio may cause severe skin reactions, including Stevens-Johnson syndrome, which can be life-threatening. If you experience any new or worsening skin problems, such as a rash, blisters, peeling skin, redness, or itching, you should contact your doctor immediately."

Answered by AI

Is teriflunomide an immunosuppressant?

"The results of the study showed that Teriflunomide and Cladribine are both effective in treating MS patients. Teriflunomide, in particular, was shown to reduce the annualized relapse rate (ARR) by more than 30% and disability progression by 30% compared to placebo."

Answered by AI

What is teriflunomide used for?

"This medicine is used to treat the relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. This medicine will not cure MS, but it may slow some disabling effects and decrease the number of relapses of the disease."

Answered by AI

Clinical Trials for Teriflunomide

Image of Jacobs School of Medicine and Biomedical Sciences, Neurology, University at Buffalo in Buffalo, United States.

Mindset Training for MS

18 - 65
All Sexes
Buffalo, NY
People with Multiple Sclerosis (MS) often experience cognitive difficulties such as memory problems, concentration issues, and reduced processing speed. These symptoms can have a negative impact on daily functioning and overall quality of life. Previous research on cognitive rehabilitation has shown that regular training focused on memory and concentration can have positive effects on cognitive functioning, including processing speed, memory, and executive functions that support daily activities. Moreover, fMRI studies (brain scans that measure brain activity) have revealed changes in brain activation following cognitive rehabilitation. Recently, the idea has emerged that a more personalized approach could improve treatment outcomes. Specifically, researchers have identified a link between personality traits and cognitive functioning. Since every individual is different, current cognitive rehabilitation programs often fail to take these personal differences into account. In this project, the investigators aim to enhance the effectiveness of cognitive rehabilitation by focusing more closely on individual characteristics through an app-based training program. Participants will complete a 12-week app training prior to a 6-week cognitive rehabilitation program. The first app focuses on mindset training, supported by a coach. Afterwards, all participants will use a second app designed to train processing speed and memory. In addition to cognitive functioning, the investigators will also examine psychological, (neuro)biological, and social changes using questionnaires and fMRI. This research may provide valuable insights into how cognitive functioning and quality of life in people with MS can be improved. This study is funded by the National MS Fund and is a collaboration between several institutions: the Department of Health, Medical and Neuropsychology at Leiden University (The Netherlands), the University at Buffalo (USA), and Reha Rheinfelden (Switzerland).
Recruiting
1 Prior Treatment
Jacobs School of Medicine and Biomedical Sciences, Neurology, University at BuffaloHanneke E Hulst, Prof
Have you considered Teriflunomide clinical trials? We made a collection of clinical trials featuring Teriflunomide, we think they might fit your search criteria.Go to Trials
Image of John D. Dingell VA Medical Center in Detroit, United States.

Ocrelizumab for Multiple Sclerosis

18 - 75
All Sexes
Detroit, MI
This study seeks to assess the effects of long-term ocrelizumab therapy on fatigue (extreme tiredness) as well as cognition (thinking and reasoning skills, such as memory, learning and attention), in veterans with multiple sclerosis. The evaluation will involve cognitive assessment scales (to assess memory, attention and learning abilities), clinical evaluations (to assess nerve function and ability to move), and patient-reported outcome measures (in which you will answer questions about your tiredness, sleep and how you function in daily life). These assessments will occur at baseline (visit 1), 6 month (Visit-2) and 12 months (visit 3) to track changes over time.
Waitlist Available
Has No Placebo
John D. Dingell VA Medical CenterGenentech, Inc.
Image of Toronto Rehabilitation Institute in Toronto, Canada.

Balance Training with Electrical Stimulation for Multiple Sclerosis

18 - 65
All Sexes
Toronto, Canada
This study will evaluate the effects of combining balance training with electrical stimulation techniques in individuals with Multiple Sclerosis (MS). MS commonly impairs leg strength, coordination, and balance, increasing the risk of falls and reducing independence. The interventions include:Balance training only, Balance training with Functional Electrical Stimulation (FES), and Balance training with FES and Transcutaneous Spinal Cord Stimulation (TSCS). FES delivers small electrical pulses to leg muscles, while TSCS delivers electrical signals through the skin to stimulate the spinal cord and enhance motor control. The study will enroll up to 24 participants over a 3-year period. This trial is funded by MS Canada. Participants will be randomly assigned to one of three groups: (1) balance training only, (2) balance training with FES, or (3) balance training with FES and TSCS. All participants will complete 12 supervised training sessions over 6 weeks. During each session, participants will engage in interactive balance games while standing in a safety harness.Outcome assessments will be conducted at three time points: baseline (prior to training), post-intervention (after 6 weeks), and follow-up (8 weeks after training). Assessments will include: * Clinical tests of mobility and balance (Timed Up and Go:TUG, 10-Meter Walk Test:10MWT, Berg Balance Scale:BBS) * Computerized balance testing using a force plate * Questionnaires on walking ability, fear of falling, and balance confidence * Neurophysiological measures of brain-spinal cord-muscle communication before and after training
Waitlist Available
Senior-friendly
Toronto Rehabilitation Institute
Image of Disability Participation and Quality of Life (DPQOL) Laboratory in Urbana, United States.

Fall Prevention Program for Multiple Sclerosis

18+
All Sexes
Urbana, IL
The research team is conducting a study to determine if a fall prevention program designed specifically for people who use wheelchairs and scooters can help people better prevent and manage falls compared to the standard of care. This study will compare two groups of participants: 1. One group will use the iROLL-O+ app, which offers personalized fall prevention tools and strategies. 2. The other group will receive fall prevention information from a well-known program developed by the Centers for Disease Control and Prevention (CDC), called STEADI, which stands for Stopping Elderly Accidents, Deaths, and Injuries. This study includes adults living with Spinal Cord Injury (SCI) or Multiple Sclerosis (MS) who use a wheelchair or scooter every day. The research team aims to determine which approach is more effective in reducing falls and improving confidence in performing daily activities.
Waitlist Available
Has No Placebo
Disability Participation and Quality of Life (DPQOL) Laboratory
Have you considered Teriflunomide clinical trials? We made a collection of clinical trials featuring Teriflunomide, we think they might fit your search criteria.Go to Trials
Image of Mayo Clinic in Rochester, United States.

Autonomic Function Testing for Multiple Sclerosis

18 - 50
All Sexes
Rochester, MN
This study looks to characterize gradients of dysfunction in the autonomic nervous system in patients with clinically diagnosed multiple sclerosis. The autonomic nervous system plays key roles in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with multiple sclerosis typically suffer. Focusing on blood pressure regulation, the most precise metric with broad clinical applicability, the investigators will perform laboratory-based tests to probe the body's ability to generate autonomic responses. For both individuals with multiple sclerosis and uninjured controls, laboratory-based experiments will utilize multiple parallel recordings to identify how the autonomic nervous system is able to inhibit and activate signals. The investigators anticipate that those with autonomic dysfunction with multiple sclerosis will exhibit abnormalities in these precise metrics. The investigators will look to see if any substantial connections exist between different degrees of preserved autonomic function and secondary autonomic complications from multiple sclerosis. In accomplishing this, the investigators hope to give scientists important insights to how the autonomic nervous system works after multiple sclerosis and give physicians better tools to manage these secondary autonomic complications.
Recruiting
Has No Placebo
Mayo Clinic
Have you considered Teriflunomide clinical trials? We made a collection of clinical trials featuring Teriflunomide, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security